(2S)-1-((2'S)-2'-Amino-3',3'-dimethylbutanoyl)pyrrolidine-2-carbonitrile hydrochloride | 341997-80-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-1-((2'S)-2'-Amino-3',3'-dimethylbutanoyl)pyrrolidine-2-carbonitrile hydrochloride
• 英文别名: (2S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile;hydrochloride
• CAS: 341997-80-6
• 化学式: C₁₁H₁₉N₃O*ClH
• 分子量: 245.752
• InChiKey: KWUAJLIUVZLHHF-OULXEKPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-1-((2'S)-2'-Amino-3',3'-dimethylbutanoyl)pyrrolidine-2-carbonitrile hydrochloride 、 甲氧基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以82%的产率得到(2S)-1-((2'S)-2'-(2-methoxybenzoylamino)-3',3'-dimethylbutanoyl)pyrrolidine-2-carbonitrile
  参考文献：
  名称：

  FAP Inhibitors

  摘要：

  本发明涉及化合物，符合一般式1，其主要用于治疗癌症。

  公开号：

  EP1760076A1

文献信息

• Novel antidiabetic agents
  申请人：——

  公开号：US20030096857A1

  公开（公告）日：2003-05-22

  Compounds which are 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2,3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R 3 CO, groups R 4 COOC(R 5 )(R 6 )OCO, methoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl; R 1 is selected from H, C 1 -C 6 alkyl residues, (CH 2 ) a NHW 1 , (CH 2 ) b COW 2 , (CH 2 ) c OW 3 , CH(Me)OW 4 , (CH 2 ) d —C 6 H 4 —W 5 and (CH 2 ) e SW 6 , where a is 2-5, b is 1-4, c is 1-2, d is 1-2, e is 1-3, W 1 is COW 6 , CO 2 W 6 or SO 2 W 6 , W 2 is OH, NH 2 , OW 6 or NHW 6 , W 3 is H or W 6 , W 4 is H or W 6 , W 5 is H, OH or OMe, and W 6 is C 1 -C 6 alkyl, optionally substituted phenyl, optionally substituted heteroaryl or benzyl and R 2 is selected from H and (CH 2 ) n —C 5 H 3 N—Y, where n is 2-4 and Y is H, F, Cl, NO 2 or CN, or R 1 and R 2 together are —(CH 2 ) p -where p is 3 or 4; R 3 is selected from H, C 1 -C 6 alkyl and phenyl; R 4 is selected from H, C 1 -C 6 alkyl, benzyl and optionally substitued phenyl; R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl or together are —(CH 2 ) m —, where m is 4-6; R 7 is selected from pyridyl and optionally substituted phenyl; R 8 is selected from H and C 1 -C 3 alkyl; and R 9 is selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and phenyl.

  根据一般式（1），1-（2'-氨基酰基）-2-氰基吡咯烷衍生物化合物是治疗糖耐量受损或2型糖尿病的DP-IV抑制剂；其中A选自2、3和4组；X选自与天然氨基酸相对应的氨基酰基、酰基R3CO、基团R4COOC（R5）（R6）OCO、甲氧羰基、乙氧羰基和苄氧羰基；R1选自H、C1-C6烷基残基、（CH2）aNHW1、（CH2）bCOW2、（CH2）cOW3、CH（Me）OW4、（CH2）d-C6H4-W5和（CH2）eSW6，其中a为2-5，b为1-4，c为1-2，d为1-2，e为1-3，W1为COW6，CO2W6或SO2W6，W2为OH、NH2、OW6或NHW6，W3为H或W6，W4为H或W6，W5为H、OH或OMe，W6为C1-C6烷基、可选取代苯基、可选取代杂环基或苄基，R2选自H和（CH2）n-C5H3N-Y，其中n为2-4，Y为H、F、Cl、NO2或CN，或R1和R2一起为—（CH2）p-，其中p为3或4；R3选自H、C1-C6烷基和苯基；R4选自H、C1-C6烷基、苄基和可选取代苯基；R5和R6各自独立地选自H和C1-C6烷基，或一起为—（CH2）m—，其中m为4-6；R7选自吡啶基和可选取代苯基；R8选自H和C1-C3烷基；R9选自H、C1-C6烷基、C1-C6烷氧基和苯基。
• FAP inhibitors
  申请人：EVANS David Michael

  公开号：US20100081701A1

  公开（公告）日：2010-04-01

  The present invention concerns compounds, according to general formula (I), which find utility preferably for the treatment of cancer.

  本发明涉及一般式（I）的化合物，其主要用于癌症治疗。
• N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS
  申请人：Ferring BV

  公开号：EP1351932A2

  公开（公告）日：2003-10-15
• FAP INHIBITORS
  申请人：Ferring B.V.

  公开号：EP1919864A2

  公开（公告）日：2008-05-14
• Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
  申请人：——

  公开号：US20040209891A1

  公开（公告）日：2004-10-21

  A method of treating an individual at risk of developing type 2 diabetes, or in the early stages thereof, so as to delay the onset and progression of the disease, which comprises the administration to the individual of repeated doses of an inhibitor of dipeptidyl peptidase IV or a prodrug thereof.